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This Symposium, presented by the Medical Sciences Section of The Ohio
Academy of Science during the 1972 annual meeting at Marietta College, achieved
one major goal of its organizers. It brought together five outstanding researchers
representing three distinct approaches to a common goal: the cure of leukemia.
The participants and audience gained much from the interaction of these dif-
fering viewpoints, although the attendance was smaller than had been hoped for.
The editors of The Ohio Journal of Science have greatly increased the value of the
Symposium by graciously agreeing to publish, as a group, three papers resulting
from the meeting and the abstract of a fourth presentation. Unfortunately it
was not possible to include the fifth paper.
A copy of the symposium program, as given in the Academy annual meeting
program follows.
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The overall tone of the Symposium was highly optimistic and the findings
presented and reviewed were both challenging and exciting. Knowledge of
leukemia has increased voluminously in the past decade, including the first real
evidence that human leukemia is caused by a virus. Now in 1972 leukemia re-
search has matured into a three-pronged study delving into (1) the cause of the
disease, (2) the mechanism through which symptoms are produced, and (3) the
improvement of clinical treatment of leukemia patients. All three approaches
are vital to the erradication of the leukemias and their threat to human life.
The virus suspected of causing leukemia in humans is of the RNA-type and its
genome may be incorporated into the genetic material of the host cell, thus making
it difficult to vaccinate against or to destroy by other means. Nevertheless, the
likelihood of a viral origin of the leukemias gives new direction to other avenues of
research. Among these are the study of the "reverse transcriptase" enzymes,
used for the incorporation of the genetic information of the virus into the chro-
mosomes of the host cell. The work on leukemia viruses and "reverse tran-
scriptases" was brilliantly described by Gallo during the Symposium and may be
reviewed in his many recent publications. Another major area is the study
of tumor and viral antigens, a study important both with the goal of identifying
"suspected cancer viruses," and with the possibility of an immunologic approach
to the cure of leukemia. The immunology of leukemia is reviewed by Yohn in
his paper appearing in this published symposium.
Another avenue of research is the study of the way the causative agent (virus)
produces the clinical symptoms of myelogenous or lymphocytic leukemia. The
study of normal white-blood-cell development (leukopoiesis) is fraught with great
complexities. The alterations of leukeopoiesis during the various leukemias are
even more difficult to determine. Perhaps because of this, the control of blood-
cell development is a fascinating area of research. One of the most intriguing
segments of this problem is that of the kinetics of human leukemic cells. How
are the rates of proliferation, maturation and destruction altered in the several
types of leukemia? The modern understanding of this question is described in
the paper by Mauer and Lampkin, who are among the foremost authorities on the
kinetics of leukemic cells.
The control of proliferation and differentiation of leukocytes may be the cause
of the altered kinetics observed in the leukemic patient. Although the control
mechanisms of human blood-cell development are still far from understood, several
substances appearing to regulate segments of leukocyte development have been
isolated. A description of the current knowledge of the development of granu-
locytic leukocytes (granulopoiesis) and recent studies on the effects of rat granu-
lopoietic control factors on murine myelogenous leukemia is presented by Graham
in the third full paper in this published symposium.
Although the basic research into the cause and nature of the leukemias has
progressed dramatically in recent years, as is well described in the first four papers
in the Symposium, today's hope and encouragement for the leukemia patient lies
in the exciting advancements in modern therapeutic means. Dr. Charles Doan,
dean emeritus of The Ohio State University College of Medicine, concluded the
Symposium with a dramatic reminder that, although the cure of leukemia lies in
the future, drug and radiation therapy have made possible survival for many of
today's patients. An abstract of his remarks concludes the collection of pub-
lished symposium materials.
Leukemia Research in 1972 can perhaps best be summarized with the thought
that both the Present and the Future are bright in cancer research. The sympo-
sium brought word both of major breakthroughs on the near horizon and of hope
and relief available today. It is to be hoped that the following papers will serve
both to encourage the lay reader that great progress is being made in cancer
research and to stimulate young people entering the field of medical science in the
knowledge that much remains to be done.
